NCT07232212Not yet recruiting
Survival Outcomes of Gynecologic Oncology Patients at Assiut University
Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Assiut University
- Diseases
- Childhood cancers
- NCT number
- NCT07232212
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2026 to the primary completion date, 1 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract
- Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)
Other
- Patients with incomplete medical records (e.g., missing pathology reports or treatment details)
Who the study is looking for
- \- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)
- Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025
- All age groups included
Sex: Female
This page is information, not medical advice. Discuss any trial with your doctor.